263 related articles for article (PubMed ID: 10515482)
21. Co-expression of immunogenic determinants by the same cellular immunogen is required for the optimum immunotherapeutic benefit in mice with melanoma.
Xu W; de Zoeten E; Carr-Brendel V; Cohen EP
Cancer Immunol Immunother; 1998 Jan; 45(5):217-24. PubMed ID: 9439644
[TBL] [Abstract][Full Text] [Related]
22. Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Collins MK; Cohen EP
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):298-304. PubMed ID: 7904182
[TBL] [Abstract][Full Text] [Related]
23. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
24. MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.
Kim TS; Cohen EP
Cancer Immunol Immunother; 1994 Mar; 38(3):185-93. PubMed ID: 8124687
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
26. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells.
Kim TS; Jung MY; Cho D; Cohen EP
Vaccine; 2006 Oct; 24(42-43):6564-73. PubMed ID: 16837111
[TBL] [Abstract][Full Text] [Related]
27. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
Toffaletti DL; Darrow TL; Scott DW
J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
[TBL] [Abstract][Full Text] [Related]
29. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
30. An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both syngeneic and allogeneic MHC-determinants.
de Zoeten EF; Markovic D; Cohen EP
Gene Ther; 2002 Sep; 9(17):1163-72. PubMed ID: 12170380
[TBL] [Abstract][Full Text] [Related]
31. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses.
Daga A; Orengo AM; Gangemi RM; Marubbi D; Perera M; Comes A; Ferrini S; Corte G
Int J Cancer; 2007 Oct; 121(8):1756-63. PubMed ID: 17582604
[TBL] [Abstract][Full Text] [Related]
32. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
Holladay FP; Lopez G; De M; Morantz RA; Wood GW
Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
[TBL] [Abstract][Full Text] [Related]
33. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system.
Kikuchi T; Joki T; Saitoh S; Hata Y; Abe T; Kato N; Kobayashi A; Miyazaki T; Ohno T
Int J Cancer; 1999 Jan; 80(3):425-30. PubMed ID: 9935185
[TBL] [Abstract][Full Text] [Related]
35. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
37. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells.
Kikuchi T; Joki T; Abe T; Ohno T
J Immunother; 1999 May; 22(3):245-50. PubMed ID: 10335484
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
40. [Effects of interferons on syngeneic murine malignant glioma-specific killer T cell].
Yamasaki T; Yamashita J; Handa H; Namda Y; Hanaoka M
No Shinkei Geka; 1983 Oct; 11(10):1059-67. PubMed ID: 6196674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]